Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Patients: A Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy

被引：3
|
作者：
Di Rocco, Alice [1 ,2 ]
Di Rocco, Arianna [3 ]
Farcomeni, Alessio [3 ]
Petrucci, Luigi [1 ]
De Luca, Giulia [1 ]
Mazzon, Federico [1 ]
Martelli, Maurizio [1 ]
Foa, Robin [1 ,4 ]
机构：
[1] Sapienza Univ, Dept Translat & Precis Med, Hematol, Rome, Italy
[2] Policlin Umberto 1, Dept Translat & Precis Med, Rome, Italy
[3] Sapienza Univ, Dept Publ Hlth & Infect Dis, Rome, Italy
[4] Sapienza Univ, Div Hematol, Dept Translat & Precis Med, Rome, Italy
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-131417
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2888
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy
    Di Rocco, Alice
    Cuneo, Antonio
    Di Rocco, Arianna
    Merli, Francesco
    De Luca, Giulia
    Petrucci, Luigi
    Ansuinelli, Michela
    Penna, Domenico
    Rotondo, Francesco
    Rigolin, Gian Matteo
    Giamo, Mariateresa
    Re, Francesca
    Farcomeni, Alessio
    Martelli, Maurizio
    Foa, Robin
    [J]. LEUKEMIA & LYMPHOMA, 2021, 62 (04) : 828 - 836
  • [2] Analysis of Patterns of Failure and the Role of Bridging Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Treated with CAR T-Cell Therapy
    Ravella, R.
    Zhang-Velten, E. R.
    Awan, F.
    Rizvi, S.
    Shah, J. L.
    Desai, N. B.
    Geethakumari, P. Ramakrishnan
    Kumar, K. A., Jr.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E305 - E306
  • [3] Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
    Dyer, Martin J. S.
    De Vos, Sven
    Ruan, Jia
    Flowers, Christopher
    Maddocks, Kami J.
    Rule, Simon
    Hamdy, Ahmed M.
    Izumi, Raquel
    Slatter, J. Greg
    Cheung, Jean
    Frigualt, Melanie M.
    Wei, Helen
    Mourya, Sanchita
    Hunder, Naomi N. H.
    Fowler, Nathan Hale
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Total Cost of Care in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Gatwood, Justin
    Masaquel, Anthony
    Ross, Ryan
    Sheinson, Danny
    Hossain, Farah
    Li, Jia
    James, Cameron
    Fox, David
    [J]. BLOOD, 2022, 140 : 7906 - 7907
  • [5] Real-world outcomes of elderly patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR-T) therapy.
    Fitzgerald, Lindsey
    Kittai, Adam
    Nastoupil, Loretta J.
    Waller, Alexandra
    Jacobson, Caron A.
    Saucier, Anna
    Kamdar, Manali K.
    Spradley, Janet
    Denlinger, Nathan
    Chipman, Jonathan
    Hu, Boyu
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] CAR T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): A 'Real-World' Analysis of Patterns of Failure and Role of Bridging Therapy
    Ravella, Revathi
    Zhang-Velten, Elizabeth Ren
    Awan, Farrukh T.
    Rizvi, Syed M.
    Shah, Jennifer L.
    Desai, Neil B.
    Geethakumari, Praveen Ramakrishnan
    Kumar, Kiran A.
    [J]. BLOOD, 2020, 136
  • [7] ROLE OF CAR-T CELLS THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
    Sen, P.
    Saadeh, B.
    Loh, E.
    [J]. VALUE IN HEALTH, 2019, 22 : S440 - S441
  • [8] Management of relapsed or refractory large B-cell lymphoma in patients ineligible for CAR-T cell therapy
    Perrone, Salvatore
    Lopedote, Paolo
    Levis, Mario
    Di Rocco, Alice
    Smith, Stephen Douglas
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (03) : 215 - 232
  • [9] Feasibility of CAR-T in very old patients with relapsed/refractory diffuse large B-cell lymphoma
    Rozental, Alon
    Chavez, Julio C.
    Sehovic, Marina
    Locke, Frederick L.
    Lazaryan, Aleksandr
    Nishihori, Taiga
    Khimani, Farhad
    Jain, Michael D.
    Shah, Bijal D.
    Extermann, Martine
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Tafasitamab (TAFA) Plus Lenalidomide (LEN) Prior to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Relapsed/ Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Case Series of 8 Patients
    Veeraputhiran, Muthu
    Mehta, Amitkumar
    Alencar, Alvaro J.
    Modi, Dipenkumar
    Voorhees, Timothy J.
    Narkhede, Mayur
    [J]. BLOOD, 2022, 140 : 12089 - 12091
12345